Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response largely aligns with the FDA label for acyclovir in indications (genital herpes, shingles, chickenpox), dosing for acute treatment and suppression, and key safety information (adverse reactions, renal adjustments, pregnancy considerations, IV use in immunocompromised). It correctly notes bioequivalence, pediatric dosing for 2 years and older, and geriatrics considerations. A notable discrepancy is the chickenpox dosing phrasing in one claim, which is actually supported by the label for adults/children >40 kg, but some immunocompromised emphasis claims are not explicit in the label. Some mechanism and historical/patent-derived statements are outside the label. Overall, the response is mostly aligned with the label with a few extraneous or mildly over-specific/inaccurate claims present in the extract.
Category Scores
Accurate Statements
Genital herpes: initial outbreaks
INDICATIONS AND USAGE; DOSAGE AND ADMINISTRATION
Genital herpes: recurrent episodes
INDICATIONS AND USAGE
Genital herpes: suppressive therapy to reduce frequency of outbreaks
DOSAGE AND ADMINISTRATION
Shingles (herpes zoster): to speed up healing
INDICATIONS AND USAGE; CLINICAL TRIALS
Shingles (herpes zoster): to alleviate pain
CLINICAL TRIALS
Chickenpox (varicella): to reduce the severity of the illness
INDICATIONS AND USAGE; CLINICAL TRIALS
Bioequivalence of dosage forms: suspension bioequivalent to capsules; 1 x 800-mg tablet bioequivalent to 4 x 200-mg capsules
Bioequivalence of Dosage Forms
Pediatrics: 2 years and older dosing for chickenpox
DOSAGE AND ADMINISTRATION
Geriatrics: dosage reduction may be required
SPECIAL POPULATIONS; PHARMACOKINETICS
Pregnancy: use if potential benefit justifies potential risk
Pregnancy
Intravenous acyclovir is indicated for varicella-zoster infections in immunocompromised patients
DOSAGE AND ADMINISTRATION
There is no information about the efficacy of therapy initiated more than 24 hours after onset of signs and symptoms
DOSAGE AND ADMINISTRATION
Acyclovir Oral Suspension is 200 mg per teaspoonful (5 mL)
HOW SUPPLIED
Unsupported Statements
Acyclovir 800mg is a prescription antiviral medication.
Label text does not explicitly state 'prescription-only' or classify its regulatory status.
Acyclovir works by inhibiting the replication of viral DNA.
Mechanism of action is not described in the label.
When a virus infects a cell, acyclovir is converted into its active form, acyclovir triphosphate, by viral enzymes.
Activation pathway is not described in the label.
Acyclovir's original patents have long expired, allowing for the production of generic versions.
Patent status is not described in the label.
Acyclovir is a foundational antiviral drug.
Not stated in the label.
Valacyclovir and famciclovir are prodrugs that are converted to acyclovir in the body.
Not described in the label.
These prodrugs often allow for less frequent dosing.
Not described in the label.
The choice of medication depends on the specific condition, patient factors, and physician's recommendation.
Not described in the label.
Decisions regarding its use in these populations are made on a case-by-case basis by healthcare professionals.
Not described in the label.
Common side effects of acyclovir include nausea, vomiting, diarrhea, headache, and dizziness.
Although common adverse events are listed, this exact enumerated phrasing is not framed as a standalone 'claim' in the label.
Acyclovir is generally not recommended for routine use in children unless specifically prescribed by a pediatrician.
Not described in the label.
Decisions regarding its use in these populations are made on a case-by-case basis by healthcare professionals.
Not described in the label.
The 800 mg four times daily dose for chickenpox in adults and children over 40 kg.
Label specifies 800 mg 4 times daily for 5 days for adults and children over 40 kg; this exact phrasing is supported (not unsupported).
Storage instructions beyond the provided storage range.
Storage detail is present, but additional non-label specifics were not evaluated here.
Contradictions
Low
AI Statement
Label Reference
Important Omissions
Mechanism of action (not described in label).
Importance:
Moderate
Contraindications section (not shown in provided label excerpt).
Importance:
Moderate
Detailed storage and handling guidance beyond the provided text.
Importance:
Low
Administration instructions beyond dosing (e.g., administration with food guidance beyond suspension absorption).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Label-supported adverse effects are generally mild to moderate; serious events are rare but include renal and neurologic events, TTP/HUS in immunocompromised as noted in warnings/adverse sections.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Minor overextension in immunocompromised emphasis for chickenpox dosing with duration claims; mechanism and historical/patent claims outside label.
Suggested Improvement
Restrict statements to label-supported indications, dosing, and safety; avoid mechanistic and historical claims; for chickenpox immunocompromised emphasis, limit to what label explicitly states (reduction in duration; treatment regimens for adults/children >40 kg).